+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain Tumor Therapeutics Market - Global Forecast to 2030- Product Image
Brain Tumor Therapeutics Market - Global Forecast to 2030- Product Image
Sale

Brain Tumor Therapeutics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011114
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain Tumor Therapeutics Market grew from USD 3.28 billion in 2024 to USD 3.56 billion in 2025. It is expected to continue growing at a CAGR of 8.27%, reaching USD 5.28 billion by 2030.

The field of brain tumor therapeutics has entered a pivotal era marked by rapid scientific advances, shifting regulatory landscapes, and evolving stakeholder demands. Enhanced molecular profiling and the integration of multi-disciplinary research have accelerated the identification of novel targets, while breakthroughs in immunotherapy and targeted agents are reshaping clinical practice. As clinicians, researchers, and industry leaders converge on unmet medical needs, the imperative to translate preclinical discoveries into safe, effective treatments has never been greater. This introduction outlines key forces driving innovation, highlights the complexity of gliomas, meningiomas, and pituitary tumors, and underscores the importance of collaboration across academia, regulatory bodies, and commercial partners. By understanding these foundational elements, decision-makers can anticipate emerging trends, align R&D portfolios with clinical needs, and navigate a competitive environment defined by rapid technological convergence. The journey from bench to bedside depends on seamless integration of diagnostics, therapeutics, and patient-centric care models, setting the stage for sustained progress against challenging central nervous system malignancies.

Transformative Shifts Redefining the Brain Tumor Therapeutics Landscape

Recent years have witnessed transformative shifts that are redefining the brain tumor therapeutics landscape. Precision oncology is fueling development of personalized regimens based on genomic signatures, enabling clinicians to deploy targeted therapies with improved efficacy and tolerability. Immunotherapy has gained momentum through the approval of checkpoint inhibitors and cancer vaccines tailored to unique tumor microenvironments, offering new hope for refractory cases. Moreover, advances in imaging techniques and artificial intelligence-driven diagnostics are enhancing early detection and treatment planning, reducing time to intervention. Combination strategies that integrate chemotherapy, radiation, and molecular agents are demonstrating synergistic effects, while novel delivery platforms such as nanoformulations and convection-enhanced approaches are overcoming blood-brain barrier challenges. Concurrently, digital health tools and remote monitoring solutions are improving patient engagement and adherence, enabling data-driven adjustments to therapy. These converging innovations are creating a dynamic ecosystem in which regulatory flexibility, strategic partnerships, and robust clinical pipelines drive rapid iterations of safe and effective treatment modalities.

Assessing the Cumulative Impact of United States Tariffs in 2025

The implementation of new United States tariffs in 2025 has exerted a cumulative impact on the brain tumor therapeutics sector, influencing supply chains, pricing strategies, and R&D investments. Tariffs on active pharmaceutical ingredients and specialized reagents have increased the cost base for manufacturers, compelling strategic sourcing decisions and negotiations with international suppliers. Equipment imports, from advanced imaging systems to precision surgical tools, now face higher duties that can delay capital expenditures and extend project timelines. As a result, some companies are exploring domestic manufacturing partnerships to mitigate tariff exposure and secure uninterrupted access to essential components. Pricing pressures have prompted a closer examination of cost-containment measures, including value-based contracting and bundled payment models, to maintain market access and reimbursement. The overall effect has underscored the need for agile supply chain management, diversified procurement strategies, and cross-border collaborations that can absorb policy shocks while sustaining innovation momentum.

Key Segmentation Insights Across Therapeutic Approaches, Tumor Types, Patient Demographics, and Drug Classes

A granular examination of key segmentation dimensions reveals pockets of robust growth and strategic opportunity. Based on therapeutic approaches, the market is studied across chemotherapy, immunotherapy, radiation therapy, surgery, and targeted therapy, with chemotherapy further subdivided into injectable, intravenous, and oral forms, immunotherapy into cancer vaccines, checkpoint inhibitors, and oncolytic virus therapy, radiation therapy into external beam and internal radiation therapy, surgery into gamma knife radiosurgery, laser interstitial thermal therapy, and open surgery, and targeted therapy into monoclonal antibodies and small molecule drugs; insights indicate that immunotherapy checkpoint inhibitors and small molecule targeted agents are driving the highest levels of clinical trial activity and commercial interest. Based on tumor type, the market is studied across gliomas, meningiomas, and pituitary tumors, with gliomas further classified into astrocytomas and oligodendrogliomas, meningiomas into anaplastic, atypical, and benign forms, and pituitary tumors into functional adenomas and nonfunctional adenomas; data suggest that glioma subtypes continue to dominate the research pipeline due to their aggressive nature and high unmet need. Based on patient type, the market is studied across adult and pediatric cohorts, with adult populations further characterized by glioblastoma multiforme and oligodendroglioma, and pediatric groups by low-grade gliomas and medulloblastomas; adult indications remain the largest commercial focus, although pediatric low-grade glioma therapies are attracting orphan drug incentives and specialized funding. Based on drug class, the market is studied across alkylating agents, which maintain a critical role in combination regimens, particularly when integrated with emerging immuno-modulatory therapies.

Regional Dynamics Shaping Global Brain Tumor Treatment Strategies

Regional dynamics are exerting a profound influence on development trajectories and market access pathways. In the Americas, streamlined regulatory frameworks and well-established reimbursement systems have fostered rapid adoption of novel agents, with real-world evidence initiatives accelerating label expansions. Europe, the Middle East & Africa present a heterogeneous environment, where European Union harmonization coexists with localized pricing constraints and evolving health technology assessment requirements, while select Middle Eastern markets are investing heavily in infrastructure to support advanced radiation and surgical platforms. In Asia-Pacific, diverse regulatory standards and expanding healthcare budgets in emerging economies are creating sizable growth corridors, spurring partnerships for technology transfer and co-development; mature markets in Japan and Australia are leveraging adaptive approval pathways and patient registry programs to expedite access. Together, these regional insights highlight the importance of tailored market entry strategies, cross-geography collaborations, and adaptive commercialization models to maximize global reach.

Strategic Profiles of Leading Companies Driving Innovation and Competition

A detailed company landscape underscores the competitive intensity and collaborative potential across the value chain. Global pharmaceutical leaders such as AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., and Sanofi S.A. are prioritizing pipeline expansion through strategic alliances, in-licensing, and internal research to bolster immunotherapy, targeted therapy, and precision diagnostics offerings. Biotech innovators including Adcendo ApS, AIVITA Biomedical, Inc., Aura Biosciences, Inc., CNS Pharmaceuticals, Inc., Curtana Pharmaceuticals, Y-mAbs Therapeutics, Inc., and Novocure GmbH are advancing cutting-edge modalities from oncolytic virus platforms to tumor-treating fields. Diagnostic and technology specialists such as Bio-Rad Laboratories, Inc., Dr. Reddy’s Laboratories Ltd., Eisai Inc., GE HealthCare Technologies Inc., Gentech, Inc., Illumina, Inc., Qiagen N.V., and Siemens Healthcare GmbH are playing critical roles in developing next-generation sequencing assays, liquid biopsy solutions, and AI-enhanced imaging tools. Collectively, these organizations are shaping innovation ecosystems, driving cross-sector partnerships, and competing on speed to market and differentiation.

Actionable Recommendations for Industry Leaders to Capitalize on Emerging Opportunities

To capitalize on emerging opportunities and mitigate evolving risks, industry leaders should implement a series of strategic actions. First, strengthen integrated R&D platforms that combine genomic profiling with immuno-modulatory screening to accelerate candidate selection and personalized therapy development. Second, diversify supply chains by establishing regional manufacturing partnerships and dual sourcing agreements to reduce exposure to policy-driven disruptions and optimize cost structures. Third, engage proactively with regulatory agencies to leverage adaptive approval pathways, real-world evidence generation, and value-based reimbursement models that align incentives across stakeholders. Fourth, foster cross-sector collaborations with digital health providers, imaging specialists, and contract research organizations to enhance trial efficiency, patient recruitment, and data analytics capabilities. Fifth, tailor commercialization strategies to regional market dynamics by aligning pricing, market access, and patient support programs with local healthcare frameworks. By executing this multifaceted agenda, organizations can maintain competitive agility, drive sustained innovation, and deliver enhanced value to patients and payers alike.

Conclusion: Navigating the Future of Brain Tumor Therapeutics with Confidence

The brain tumor therapeutics sector stands at the intersection of scientific promise and commercial complexity. By integrating precision medicine, advanced diagnostics, and digital health solutions, stakeholders are positioned to overcome longstanding barriers and address significant unmet clinical needs. Regional nuances, regulatory evolution, and policy shifts such as tariff reforms underscore the importance of adaptive strategies and resilient operations. As leading companies refine segmentation insights, expand strategic alliances, and navigate shifting market access landscapes, the cumulative effect will be a richer pipeline of efficacious treatments and improved patient outcomes. The collective effort of researchers, clinicians, manufacturers, payers, and policymakers will determine the trajectory of innovation and the pace at which transformative therapies reach those in need.

Market Segmentation & Coverage

This research report categorizes the Brain Tumor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Chemotherapy
    • Injectable
    • Intravenous
    • Oral
  • Immunotherapy
    • Cancer Vaccines
    • Checkpoint Inhibitors
    • Oncolytic Virus Therapy
  • Radiation Therapy
    • External Beam Radiation
    • Internal Radiation Therapy
  • Surgery
    • Gamma Knife Radiosurgery
    • Laser Interstitial Thermal Therapy
    • Open Surgery
  • Targeted Therapy
    • Monoclonal Antibodies
    • Small Molecule Drugs
  • Gliomas
    • Astrocytomas
    • Oligodendrogliomas
  • Meningiomas
    • Anaplastic
    • Atypical
    • Benign
  • Pituitary Tumors
    • Functional Adenomas
    • Nonfunctional Adenomas
  • Adult
    • Glioblastoma Multiforme
    • Oligodendroglioma
  • Pediatric
    • Low-Grade Gliomas
    • Medulloblastomas
  • Alkylating Agents

This research report categorizes the Brain Tumor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Brain Tumor Therapeutics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Adcendo ApS
  • AIVITA Biomedical, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aura Biosciences, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CNS Pharmaceuticals, Inc.
  • Curtana Pharmaceuticals
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc.
  • Gentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Merck KGaA
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Qiagen N.V.
  • Sanofi S.A.
  • Siemens Healthcare GmbH
  • Y-mAbs Therapeutics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Brain Tumor Therapeutics Market, by Therapeutic Approaches
8.1. Introduction
8.2. Chemotherapy
8.2.1. Injectable
8.2.2. Intravenous
8.2.3. Oral
8.3. Immunotherapy
8.3.1. Cancer Vaccines
8.3.2. Checkpoint Inhibitors
8.3.3. Oncolytic Virus Therapy
8.4. Radiation Therapy
8.4.1. External Beam Radiation
8.4.2. Internal Radiation Therapy
8.5. Surgery
8.5.1. Gamma Knife Radiosurgery
8.5.2. Laser Interstitial Thermal Therapy
8.5.3. Open Surgery
8.6. Targeted Therapy
8.6.1. Monoclonal Antibodies
8.6.2. Small Molecule Drugs
9. Brain Tumor Therapeutics Market, by Tumor Type
9.1. Introduction
9.2. Gliomas
9.2.1. Astrocytomas
9.2.2. Oligodendrogliomas
9.3. Meningiomas
9.3.1. Anaplastic
9.3.2. Atypical
9.3.3. Benign
9.4. Pituitary Tumors
9.4.1. Functional Adenomas
9.4.2. Nonfunctional Adenomas
10. Brain Tumor Therapeutics Market, by Patient Type
10.1. Introduction
10.2. Adult
10.2.1. Glioblastoma Multiforme
10.2.2. Oligodendroglioma
10.3. Pediatric
10.3.1. Low-Grade Gliomas
10.3.2. Medulloblastomas
11. Brain Tumor Therapeutics Market, by Drug Class
11.1. Introduction
11.2. Alkylating Agents
12. Americas Brain Tumor Therapeutics Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Brain Tumor Therapeutics Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Brain Tumor Therapeutics Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. Adcendo ApS
15.3.3. AIVITA Biomedical, Inc.
15.3.4. Amgen Inc.
15.3.5. AstraZeneca PLC
15.3.6. Aura Biosciences, Inc.
15.3.7. Bayer AG
15.3.8. Becton, Dickinson and Company
15.3.9. Bio-Rad Laboratories, Inc.
15.3.10. Bristol-Myers Squibb Company
15.3.11. CNS Pharmaceuticals, Inc.
15.3.12. Curtana Pharmaceuticals
15.3.13. Dr. Reddy’s Laboratories Ltd.
15.3.14. Eisai Inc.
15.3.15. Eli Lilly and Company
15.3.16. F. Hoffmann-La Roche AG
15.3.17. GE HealthCare Technologies Inc.
15.3.18. Gentech, Inc.
15.3.19. GlaxoSmithKline PLC
15.3.20. Illumina, Inc.
15.3.21. Johnson & Johnson Services, Inc.
15.3.22. Merck & Co. Inc.
15.3.23. Merck KGaA
15.3.24. Novartis AG
15.3.25. Novocure GmbH
15.3.26. Pfizer Inc.
15.3.27. Qiagen N.V.
15.3.28. Sanofi S.A.
15.3.29. Siemens Healthcare GmbH
15.3.30. Y-mAbs Therapeutics, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BRAIN TUMOR THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. BRAIN TUMOR THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. BRAIN TUMOR THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BRAIN TUMOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BRAIN TUMOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRAIN TUMOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY INTERNAL RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GAMMA KNIFE RADIOSURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ASTROCYTOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY OLIGODENDROGLIOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ANAPLASTIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY BENIGN, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY FUNCTIONAL ADENOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY NONFUNCTIONAL ADENOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY LOW-GRADE GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MEDULLOBLASTOMAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 99. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 100. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 101. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 102. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 103. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 104. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 105. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 106. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 107. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 108. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 110. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 111. CANADA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 113. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 114. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 116. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 117. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 118. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 119. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 121. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 122. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 141. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 169. AUSTRALIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 171. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 172. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 173. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 174. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 175. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 176. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 177. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 178. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 179. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 180. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 181. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 182. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 183. CHINA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 184. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 185. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 186. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 187. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 188. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 189. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 190. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 191. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 192. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 193. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 194. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 196. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 197. INDIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 208. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 210. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 211. INDONESIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 213. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 214. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 215. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 216. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 217. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 218. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 219. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 220. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 221. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 222. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 223. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 224. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 225. JAPAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 227. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 228. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 229. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 234. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 235. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 236. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 238. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 239. MALAYSIA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 241. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 242. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 243. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 247. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 248. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 249. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 250. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 251. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 252. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 253. PHILIPPINES BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 254. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 255. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 257. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 260. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 261. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 262. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 263. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 264. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 265. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 266. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 283. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 284. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 285. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 286. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 287. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 288. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 289. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 290. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 291. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 292. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 293. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 294. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 295. TAIWAN BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 296. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 297. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 298. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 299. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 300. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 301. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 302. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 303. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 304. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 305. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 306. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 307. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 308. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 309. THAILAND BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 310. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 316. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
TABLE 317. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY GLIOMAS, 2018-2030 (USD MILLION)
TABLE 318. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY MENINGIOMAS, 2018-2030 (USD MILLION)
TABLE 319. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PITUITARY TUMORS, 2018-2030 (USD MILLION)
TABLE 320. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 321. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 322. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 323. VIETNAM BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 324. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACHES, 2018-2030 (USD MILLION)
TABLE 325. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 326. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 327. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 328. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TAB

Companies Mentioned

  • AbbVie Inc.
  • Adcendo ApS
  • AIVITA Biomedical, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aura Biosciences, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • CNS Pharmaceuticals, Inc.
  • Curtana Pharmaceuticals
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc.
  • Gentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Merck KGaA
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Qiagen N.V.
  • Sanofi S.A.
  • Siemens Healthcare GmbH
  • Y-mAbs Therapeutics, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Brain Tumor Diagnosis & Therapeutics Market - Global Forecast to 2030 - Product Image

Brain Tumor Diagnosis & Therapeutics Market - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Brain Tumor Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Type (Primary, Secondary), Product, Diagnosis (MRI, CT, PET-CT), Therapeutics, End Use, and Region with Growth Forecasts, 2025-2030 - Product Image

Brain Tumor Diagnosis and Therapeutics Market Size, Share & Trends Analysis Report by Type (Primary, Secondary), Product, Diagnosis (MRI, CT, PET-CT), Therapeutics, End Use, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Brain Tumor Diagnosis & Treatment Market - Global Forecast to 2030 - Product Image

Brain Tumor Diagnosis & Treatment Market - Global Forecast to 2030

  • Report
  • 195 Pages
  • Global
From
Brain Tumor Therapeutics - Global Strategic Business Report - Product Image

Brain Tumor Therapeutics - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Brain Tumor Drugs Market Report 2025 - Product Image

Brain Tumor Drugs Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.